3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
6
Recruiting
4
Terminated
2
Withdrawn
1
Unknown
1
Not yet recruiting
1
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
25
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Leukemia
9
Lymphoma, Large B-Cell, Diffuse
8
Lymphoma
8
Burkitt Lymphoma
6
Recurrence
5
Lymphoma, Follicular
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Non-Hodgkin
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, Large-Cell, Anaplastic
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Leukemia, Biphenotypic, Acute
4
Sezary Syndrome
3
Myelodysplastic Syndromes
3
Mycosis Fungoides
3
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Immunoblastic Lymphadenopathy
3
Hodgkin Disease
3
Blast Crisis
3
Waldenstrom Macroglobulinemia
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Extranodal NK-T-Cell
2
Lymphoma, B-Cell
2
Lymphoma, AIDS-Related
2
Leukemia, Myelomonocytic, Chronic
2
Interventions
siremadlin
1
selinexor
1
posaconazole
1
midostaurin
1
fludarabine
1
durvalumab
1
blinatumomab
1
avelumab
1
Radiosurgery
1
Midazolam
1
Lenalidomide
1
Idarubicin
1
Dexamethasone
1
Daunorubicin
1
Cytarabine
1
Cyclophosphamide
1
Calcium Dobesilate
1
Azacitidine
1
Anthracyclines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Neoplasm, Residual
×
Cytarabine
×
Clear all
NCT03760445
2020-01-09
HDM201 Added to CT in R/R or Newly Diagnosed AML
Novartis
Phase 1/2
Withdrawn